Cardiometabolic Diseases Market worth USD 121,804.49 million by 2028 - Exclusive Research by The Insight Partners

The cardiometabolic diseases market is expected to reach US$ 121,804.49 million by 2028 from US$ 93,494.41 million in 2021; it is estimated to grow at a CAGR of 3.9% during 2021-2028.

The report highlights trends prevailing in the market and factors driving its growth. The market growth is mainly attributed to factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, the under diagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.

Get Sample PDF Copy of Cardiometabolic Diseases Market at:
https://www.theinsightpartners.com/sample/TIPRE00025374/?utm_source=OpenPR&utm_medium=10408

Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.

Based on type, the cardiometabolic diseases market is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment held the largest share of the market in 2021, and the segment is anticipated to register the highest CAGR in the market during the forecast period. CVDs are a group of conditions of the heart and blood vessels. Types of CVDs are coronary heart disease, cerebrovascular disease, heart failure, congenital heart disease, deep vein thrombosis, peripheral arterial disease, and rheumatic heart disease. Heart attacks and strokes are acute events caused by a blockage that prevents blood from flowing to the heart or brain. Congestive heart failure (CHF) happens when the heart's function as a pump is inadequate to meet the body's needs. Common causes of heart failure are coronary artery disease, high blood pressure, and diabetes. As per Emory Healthcare, ~550,000 new cases of CHF are diagnosed in the US each year.

Impact of COVID-19 Pandemic on Cardiometabolic Diseases Market:
The COVID-19 pandemic is adversely affecting industries worldwide. The outbreak led to significant disruptions in primary industries, such as manufacturing, healthcare, energy & power, electronics & semiconductor, aerospace & defense, and construction, in 2020. However, it provided a vital growth opportunity to the cardiovascular diseases market players. As per the Cleveland Clinic, ~15% of patients suffering from CVD and up to 20% of patients who have undergone coronary artery bypass graft surgery are under major depression. Even mild depression, such as a depressed mood, can increase the risk of coronary artery disease. Restrictive measures taken during the COVID-19 pandemic might have increased depression in patients affected by cardiovascular diseases. According to MedTech Europe, around 95% of all COVID-19 deaths had at least one underlying condition, with cardiovascular disease being the leading comorbidity (65%). Also, around 50% decrease in the number of people visiting hospitals and other health care facilities with symptoms of heart attacks or stroke is creating a significant backlog of patients with severe health conditions. The pandemic has significantly negatively impacted the cardiometabolic diseases market in the short term. However, the market will grow at a moderate pace during the forecast period.

Speak to Analyst for more details:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00025374?utm_source=OpenPR&utm_medium=10408

Cardiometabolic Diseases Market: Competitive Landscape and Key Developments
Eli Lilly and Company; Bayer AG; Arrowhead Pharmaceuticals, Inc; Novartis AG; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; AstraZeneca; Alnylam Pharmaceuticals, Inc.; Cardax, Inc.; and Kowa Company, Ltd are among the leading companies operating in the cardiometabolic diseases market.

Market Insights
Increasing Prevalence of Cardiometabolic Diseases
Cardiometabolic diseases (CMDs) are one of the leading causes of death worldwide. These diseases are mainly caused by an unhealthy lifestyle, physical inactivity, smoking, and an unhealthy diet. CMDs include cardiovascular diseases (CVDs), diabetes mellitus, and chronic renal failure. As per the WHO, around 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.

Most cardiovascular diseases can be prevented by addressing behavioral risk factors, such as tobacco intake, unhealthy dietary choices, obesity, physical inactivity, and alcohol consumption. Diabetes is one of the life-threatening chronic diseases with no functional cure. It leads to various complications and increases the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As per the International Diabetes Federation (IDF), in 2019, ~463 million adults were living with diabetes, which is expected to reach 700 million by 2045.

Order a Copy of Cardiometabolic Diseases Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00025374/?utm_source=OpenPR&utm_medium=10408

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.